21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Dormancy antigens as biomarkers of latent tuberculosis infection

      discussion
      a , * , b
      EBioMedicine
      Elsevier

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mycobacterium tuberculosis (MTB) is a major microbial pathogen that threatens global health. The WHO has estimated about 9 million new tuberculosis (TB) cases and around 1.5 million deaths due to TB in the year 2013 (World Health Organization, 2014). In MTB-infected individuals, bacteria may exist in a dormant state for lengthy periods without causing disease symptoms, or may finally start multiplying and evading immune control, resulting in active TB in 5–10% of infected cases. At present, factors that promote progression from latent tuberculosis infection (LTBI) to disease are not totally understood. Therefore, management of LTBI plays a significant role for TB disease control given that quiescent bacilli are a big reservoir of potential TB cases. Tuberculin skin test (TST) has been the classical method used for LTBI diagnosis in spite of its compromised specificity due to cross-reaction with Mycobacterium bovis bacillus Calmette–Guérin (BCG) vaccine strain and non-tuberculous mycobacteria. Furthermore, it has low sensitivity in immune compromised patients, who are in particular those that mainly need this test because they have a high risk of developing active TB if they are infected. Interferon (IFN)-γ release assays (IGRAs) appeared more than a decade ago as an alternative method to TST for diagnosing LTBI. They detect the IFN-γ released by sensitized T cells after stimulation with specific MTB antigens encoded in the region of difference (RD) 1 and 11 (ESAT-6, CFP-10 and TB7.7) (Andersen et al., 2000). Nowadays, IGRAs implementation has improved LTBI diagnosis because of their higher specificity with respect to TST and good correlation with MTB exposure degree; however, they do not discriminate between LTBI and active TB (Pai et al., 2014). As a consequence, there is a need for studying new biomarkers to explore the biology and the immune response for distinguishing latency from disease. At present, some new MTB phase-dependent antigens have been studied in LTBI individuals and active TB patients showing promising results. These studies explore the response of T cells producing IFN-γ because they are the major players in the protection against TB. However, variable results regarding these antigens have been obtained since now due to disparities in methodology and population heterogeneity (Serra-Vidal et al., 2014; Goletti et al., 2010; Singh et al., 2014). In EBioMedicine, Delfina Peña and colleagues (Peña et al., 2015) have investigated the efficacy of several DosR regulon-encoded latency antigens as potential markers for LTBI. The antigens included and studied in this work were Rv2624c, Rv2626c, and Rv2628; together with ESAT-6 and CFP-10. Interestingly, Rv2626c was found to produce significant IFN-γ levels in BCG LTBI individuals with respect to active TB patients or healthy controls. In a first approach, the response to MTB antigens was investigated stimulating peripheral blood mononuclear cells (PBMCs) from BCG LTBI individuals (QFT-GIT positive) and healthy controls (QFT-GIT negative), finding that IFN-γ response was significantly higher in LTBI individuals with respect to healthy controls upon Rv2626c stimulation. Interestingly, these findings were also confirmed by flow cytometry. Then, in a second approach, the IFN-γ response to Rv2626c was also analyzed in a third group of active TB patients stimulating PBMCs and whole blood with this specific antigen. In contrast to the results obtained with RD1 antigens (ESAT-6 and CFP-10), stimulation with this latency antigen allowed to discriminate between active and latent infection since patients with active TB did not secrete IFN-γ against Rv2626c. Finally, these results were also reinforced by a ROC analysis. Investigators also identified several specific and immunogenic Rv2626c immunodominant peptide pools that improved LTBI diagnosis. Delfina Peña and colleagues study (Peña et al., 2015) investigates an interesting and promising field; as a consequence, their results are encouraging for several reasons. First, as currently IGRAs are not designed for distinguishing between LTBI and disease; investigations based on new antigens linked to latency are required. In this sense, the novel Rv2626c antigen studied in the present work could be promising and improve LTBI diagnosis. However, further investigations on other latency antigens different from those contemplated in this study are still required. Second, the study of new immune-biomarkers for detecting IFN-γ in vitro may open the door to the development of next generation assays based on new antigens. Furthermore, potential host biomarkers are urgently needed to provide risk of LTBI progression as well. In this sense, a recent published study have assessed the utility of measuring IFN-γ/TNF-α ratio against 16 antigens, finding that Rv2626c and Rv3716c improved QFT-GIT diagnostic performance and LTBI diagnosis (Prabhavathi et al., 2015). In addition, the use of flow cytometry is currently being utilized for the study of the immune response and cell surface marker expression (immunophenotyping) in order to find a signature related with infection or disease (Harari et al., 2011; Portevin et al., 2014). Together these findings will help to develop and design novel state-of-the-art techniques for LTBI and active TB diagnosis in not so near distant future. Conflict of interest We declare no competing interests.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: not found

          Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease.

          Rapid diagnosis of active Mycobacterium tuberculosis (Mtb) infection remains a clinical and laboratory challenge. We have analyzed the cytokine profile (interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2)) of Mtb-specific T cells by polychromatic flow cytometry. We studied Mtb-specific CD4+ T cell responses in subjects with latent Mtb infection and active tuberculosis disease. The results showed substantial increase in the proportion of single-positive TNF-α Mtb-specific CD4+ T cells in subjects with active disease, and this parameter was the strongest predictor of diagnosis of active disease versus latent infection. We validated the use of this parameter in a cohort of 101 subjects with tuberculosis diagnosis unknown to the investigator. The sensitivity and specificity of the flow cytometry-based assay were 67% and 92%, respectively, the positive predictive value was 80% and the negative predictive value was 92.4%. Therefore, the proportion of single-positive TNF-α Mtb-specific CD4+ T cells is a new tool for the rapid diagnosis of active tuberculosis disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Specific immune-based diagnosis of tuberculosis.

            Current diagnostic tests for tuberculosis based on tuberculin have poor specificity, and both BCG vaccination and exposure to non-tuberculosis mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis. The identification of regions of the M. tuberculosis genome that are not present in BCG and non-tuberculous mycobacteria provides a unique opportunity to develop new highly specific diagnostic reagents. We describe the current status of attempts to exploit this information and summarise recent research that has used defined antigens for an accurate and rapid test for tuberculosis infection based on the detection of T cells sensitised to M. tuberculosis either by blood tests in vitro or skin tests in vivo.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection.

              Interferon-gamma release assays based on region of difference 1 antigens have improved diagnosis of latent tuberculosis infection (LTBI). However, these tests cannot discriminate between recently acquired infection (higher risk of progression to active tuberculosis) and remote LTBI. The objective of the present study was to evaluate the T-cell interferon-gamma responses to Mycobacterium tuberculosis DosR-regulon-encoded antigens (latency antigens) compared with QuantiFERON TB-Gold In-Tube (QFT-GIT) in subjects at different stages of tuberculosis. A total of 16 individuals with remote LTBI and 23 with recent infection were studied; 15 controls unexposed to M. tuberculosis and 50 patients with active tuberculosis and 45 with cured tuberculosis were also analysed. The results indicated that subjects with remote LTBI showed significantly higher whole-blood interferon-gamma responses to M. tuberculosis latency antigen Rv2628 than did individuals with recent infection, active tuberculosis and controls (p<0.003), whereas no significant differences between these groups were found for other latency antigens tested (Rv2626c, Rv2627c, Rv2031c and Rv2032). The proportion of responders to Rv2628 was five-fold higher among QFT-GIT-positive-individuals with remote infection than among those with recently acquired infection. These data suggest that responses to M. tuberculosis latency antigen Rv2628 may associate with immune-mediated protection against tuberculosis. In contact-tracing investigations, these preliminary data may differentiate recent (positive QFT-GIT results without responses to Rv2628) from remote infection (positive to both tests).
                Bookmark

                Author and article information

                Contributors
                Journal
                EBioMedicine
                EBioMedicine
                EBioMedicine
                Elsevier
                2352-3964
                19 June 2015
                August 2015
                19 June 2015
                : 2
                : 8
                : 788-789
                Affiliations
                [a ]Molecular Microbiology Department, Hospital Universitari Sant Joan de Déu, University of Barcelona, Barcelona, Spain
                [b ]Institut d'Investigació Germans Trias i Pujol, Universitat Autònoma de Barcelona, CIBER Enfermedades Respiratorias (CIBERES), Badalona, Spain
                Author notes
                [* ]Corresponding author at: Department of Molecular Microbiology, Hospital Sant Joan de Déu, University of Barcelona, P Sant Joan de Deu, 2, 08950 Esplugues, Barcelona, Spain. irelatorre@ 123456gmail.com
                Article
                S2352-3964(15)30046-3
                10.1016/j.ebiom.2015.06.017
                4563125
                e84dde55-787a-41d1-ba48-de0bc706c559
                © 2015 The Authors. Published by Elsevier B.V.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 17 June 2015
                : 18 June 2015
                Categories
                Commentary

                Comments

                Comment on this article